Bicycle Therapeutics Ltd, a Babraham Research Campus, Cambridge, UK-based biotechnology company developing a novel technology platform for the identification and optimisation of chemically constrained cyclic peptides with high target specificity and binding affinity, received additional seed funding.
New investors include SR One, the independent corporate venture fund of GlaxoSmithKline, and SV Life Sciences. In conjunction with the funding, Dr Debbie Harland, SR One, and Kate Bingham, SVLS, have joined the board of directors of the company.
Founding investors Atlas Venture and Novartis Venture Fund also participated in the round.
Bicycle, a spin-out from the MRC Laboratory of Molecular Biology, Cambridge, has also signed a License agreement with the Ecole Polytechnique Federale de Lausanne (EPFL) in Lausanne, Switzerland.
The company’s technology platform is based on the pioneering work at the LMB of the founding scientists Sir Gregory Winter, a scientific founder of both CAT and Domantis, and Dr. Christian Heinis, currently Assistant Professor at the Institute of Chemical Sciences and Engineering (ISIC) at EPFL.
The License Agreement with EPFL is aimed to strengthen the ongoing relationship between Bycicle and the laboratory.
Founded in July 2009, the company is managed by Dr John Tite (CEO).